Introduction
Glucuronidation is an important reaction in the metabolism of drugs. UDPglucuronosyltransferases (UGTs) are primarily involved in the conjugation of metabolites from oxidation reactions. However, if a suitable electrophilic acceptor group is present, UGTs can also conjugate drugs directly without any prior oxidation step. Recently, there has been an increasing awareness of the importance of glucuronidation, especially in drug development (Williams et al., 2004) . Therefore, the prediction of human pharmacokinetics (PK) from both oxidative and conjugative preclinical metabolism data is an important goal in the drug discovery and development process to ultimately choose the best drug candidates for clinical study, and to minimize risk to participants during first-in-human studies.
Several approaches have been developed for providing quantitative predictions of human PK and have been increasingly integrated into all stages of the drug research process (Shibata et al., 2002; Soars et al., 2002; Hosea et al., 2009) . These predictive approaches typically use either empirical (e.g., animal in vivo preclinical data) or mechanistic (using in vitro human tissue such as microsomes or hepatocytes) methods. However, prediction of clearance (CL) from microsomal in vitro data has shown a general trend toward underprediction (Kilford et al., 2009) , with studies reporting 10-to 30-fold underprediction of CL (Miners et al., 2006) . Allometric scaling is widely used in predicting human CL based on animal data. Since prediction errors are commonly observed in the practical application of this approach, various modifications to allometric scaling have been proposed (Ward and analyzed individually for the parent drug by LC/MS/MS. Parameter estimates of plasma CL and distribution volume at steady state (V ss ) were obtained from non-compartmental analysis using WinNonlin (Pharsight, Mountain View, CA) of individual plasma concentration-time profiles obtained following intravenous dosing. Each CL was converted to blood CL (CL B ) by correcting with the blood to plasma concentration ratio (R B ) determined from in vitro methods (n=3) (Izumi et al., 1996) . Oral bioavailability (F) was estimated by the doseadjusted area under the concentration-time curve ratio following single oral and intravenous administration.
Prediction Methodologies
Methods for the prediction of human CL, V ss , F, oral clearance (CL po ) and half-life (t 1/2 ) employed in the analysis are shown below (Hosea et al., 2009) . Human CL and V ss were predicted using allometry of CL B with the ROE (eq. 1), SSS of CL B (eq. 2), allometry of V ss (eq. 3) and SSS of V ss , which was estimated by assuming that the human volume would be identical to that in one of the preclinical animals. 
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CL po,human = CL human /F human (5)
Human t 1/2 was predicted from the combination of individual CL and V ss predictions from the same species (eq. 6). f m,UGT = (C bile x V bile + C urine x V urine )/Dose (7) where, C bile , C urine , V bile and V urine are the concentrations of glucuronide excreted in bile and urine (μmol/mL), the volume of bile and urine samples (mL), respectively.
Analytical Methods
The LC/MS/MS systems used consisted of a Alliance 2795 (Waters, Elstree, UK) with a Micromass Quattro Premier mass spectrometer (Waters) or Prominence LC-20A system (Shimadzu Corp., Kyoto, Japan) with API 4000 (Applied Biosystems/MDS SCIEX, Foster City, CA). Varying gradients of four mobile phases were used, the compositions of which were (1) 5 mM ammonium acetate and 0.2% formic acid with 5% acetonitrile, (2) 5 mM ammonium acetate and 0.2% formic acid with 95% acetonitrile, (3) 5 mM ammonium acetate with 5% acetonitrile and (4) 5 mM ammonium acetate with 95% acetonitrile. A CAPCELL PAK MG II C18 column 3 μ m, 20 mmID x 50 mm (Shiseido, Tokyo, Japan) was used for chromatographic separation of analytes at 40°C. The flow rate was 0.5 ml/min.
Further analytical parameters are described in Table 1 . The ion chromatograms were integrated and quantified based on analyte/internal standard peak-area ratios using Micromass QuanLynx software (Waters) or Analyst data system (Applied Biosystems/MDS SCIEX). Phenacetin or niflumic acid was used as the internal standard for the analysis in the positive ion mode, and furosemide or niflumic acid was used in the negative ion mode.
Results

Preclinical Parameters
The f u as determined by ultracentrifugation and R B for all compounds are summarized in Table 2 . The f u ranged from 0.002 to 0.922, and the R B ranged from 0.46 to 2.13.
Mean non-compartmental PK parameter estimates of plasma CL, V ss and F determined from in vivo PK studies conducted in mice, rats, monkeys and dogs are summarized in Table   3 . Imipramine, lorazepam, zidovudine and raloxifene represented relatively large plasma CL in preclinical animals. V ss values for imipramine, lorazepam, levofloxacin, zidovudine, raloxifene, gemfibrozil, mycophenolic acid, indomethacin and telmisartan were more than 1 L/kg in some animals. Imipramine, lorazepam and raloxifene showed low F in preclinical animals. Table 4 summarizes the predicted and observed values of the PK parameters for the twelve drugs in humans. Prediction methods including allometric scaling with the ROE using multiple species and SSS of mice, rats, monkeys and dogs were applied to the preclinical data sets (Tables 2 and 3) to predict human CL, V ss and F. These primary PK parameters were used to estimate CL po and t 1/2 , and predicted parameters were compared to the actual values observed in humans. The percentage of compounds for which the PK parameters were predicted within 2-fold, 3-fold and 4-fold of the actual values was determined for each method. Multiple-species allometry with the ROE and SSS of mice, rats and dogs resulted in a similar percentage of compounds whose CL and CL po predictions fell within 3-fold of actual (Table 4 ). The SSS of monkeys predicted human CL and CL po within 2-fold of actual for 58% and 50%, and within 3-fold of actual for 83% and 67%, respectively, resulting in the highest accuracy of all methods analyzed. When employing data from SSS of This article has not been copyedited and formatted. The final version may differ from this version. mice and rats ( Fig. 1 and 2 ), trend of underprediction for CL and CL po was observed in contrast with those from monkeys and dogs.
Comparison of Prediction Methods
Predictions for V ss , multiple-species allometry, SSS of mice, rats, monkeys and dogs resulted in 58%, 17%, 42%, 58% and 50%, falling within 2-fold; and 67%, 50%, 67%, 67%
and 58%, respectively, falling within 3-fold prediction accuracy ( Fig. 3 and Table 5 ). The ability to predict V ss within 3-fold was similar between multiple-species allometry and SSS of each species. The accuracy of allometric scaling methods using unbound CL and unbound V ss tended to be less successful than those using CL and V ss (data not shown). Some f u values of test drugs were less than 0.01, which may decrease their predictability.
In the prediction for human t 1/2 , multiple-species allometry, SSS of mice, rats, monkeys and dogs resulted in 42%, 25%, 42%, 58% and 42%, falling within 2-fold; and 50%, 33%, 67%, 67% and 50%, respectively, falling within 3-fold prediction accuracy ( Fig. 4 and Table   5 ). The ability to predict t 1/2 within 3-fold was more accurate in SSS of rats and monkeys.
Comparison of f m,UGT
Although in vivo f m,UGT values in humans were estimated from only renal excretion in the literature, most of those values in preclinical animals, estimated from biliary and urinary excretion, were smaller than those in humans ( Fig. 5 and Table 6 ). f m,UGT values in monkeys were relatively similar to those of humans as compared to other animal species, which likely contributed to the highest accuracy of SSS prediction of monkeys. The median values of f m,UGT ratios (f m,UGT in animals/f m,UGT in humans) were within 2-fold identity in monkeys; however, they were smaller in other animal species.
Discussion
In the present study, we evaluated the accuracy of allometric scaling methods for drugs metabolized by UGTs. Human PK parameters were predicted by multiple-species allometry with the ROE and SSS of mice, rats, monkeys and dogs, and compared with observed values reported in the literature. In the current analysis of CL and CL po (Table 4) , the prediction accuracy of multiple-species allometry with the ROE and SSS of rats, monkeys and dogs was similar to that previously reported in which the compounds assessed were eliminated by various metabolic processes, including P450-and/or non-P450-mediated metabolism, active transport and passive renal elimination (Tang et al., 2007; Hosea et al., 2009) . Therefore, it is suggested that allometric scaling approaches could predict human PK of UGT substrates as One key observation from this study is that the monkey is an important species for extrapolating CL and CL po . In the present analysis for predicting human CL by SSS, a fixed allometric exponent of 0.75 was assumed based on the fact that physiological factors (metabolic rate, tissue weight, blood flow rate, blood volume, passive renal CL, oxygen consumption, etc.) can be scaled among species (White and Seymour, 2005 2004; Tang et al., 2007; Hosea et al., 2009) . However, when employing data from SSS of rats ( Fig. 1 and 2) , trend of underprediction for CL and CL po was observed. It may be explained by the species differences of metabolic activity, dominant enzyme isoforms or enterohepatic circulation (Ruelius, 1978; Collins, 2001; Miles et al., 2005) .
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An increasing awareness of the importance of conjugation metabolism has led to a need for the incorporation of these pathways into drug CL prediction. In the present study, zidovudine, levofloxacin and telmisartan showed dramatic differences of f m,UGT between humans and animals ( Table 6 ). There are three possibilities to explain this: 1) species differences of glucuronidation, 2) stability of glucuronide and 3) limited availability of human data. As previously mentioned, zidovudine is known to show species differences of glucuronidation between humans and preclinical animals ( determined only from urinary excretion was used in this study, suggesting the potential risk to misread the species differences. However, considering most cases showed that f m,UGT in humans was higher than that in animals ( Predictions are from (A) allometry with the ROE and F a x F g from monkeys; and SSS and F a x F g of (B) mice, (C) rats, (D) monkeys and (E) dogs. In each SSS prediction (B -E), the product of F a and F g from the corresponding animal was used. The solid, dotted and dashed lines represent the lines of identity, 2-fold and 3-fold identity, respectively. Duggan et al., 1972) .
